Symposium de Menselijke Maat: Radiotherapie 2035

09.30 – 10.00	**Ontvangst**	
10.00 – 10.15	**Welkomstwoord** *Joost Verhoeff en Ben Slotman*	
10.15 – 10.45	**Louis Vermeulen** *Future of oncology: No more radiotherapy needed?*	
10.45 – 11.15	**Peter Hoskin** *Future of radiotherapy: isotopes or beams?*	
11.15 – 11.45	**Dave Fuller** *Future of MR-guided radiotherapy & MR biomarker validation*	
11.45 – 12.15	**Matthias Guckenberger** *Future of clinical trial design and MRI-informed vs hybrid systems*	
12.15 – 13.15	**Lunch**	
13.15 – 13.45	**Liz Salmi** *Future of patient-clinician communication*	
13.45 – 14.15	**Jolanda van Boven** *De AVG: Van drempel naar springplank*	
14.15 – 14.45	**Mathieu Weggeman** *Leidinggeven aan medische professionals? Niet doen!*	
14.45 – 15.00	**Afsluiting en dankwoord** *Joost Verhoeff en Ben Slotman*	

De Veranda, Amstelveenseweg 764, 1081 JK Amsterdam

Meet the Speakers: Biographies in Brief

Professor Ben Slotman is former Chairman of Department of Radiation Oncology at the Amsterdam UMC. Professor Slotman received his MD in 1985 and PhD in 1990, both with highest honors at VU University in Amsterdam, The Netherlands and he was registered as radiation oncologist in 1994. He is former president of the American Radium Society (ARS), past-president of ESTRO and president of the Radiosurgery Society (RSS). Ben Slotman is co-founder and first president of the International Radiation Oncology Societies Network (IRON).

Professor Louis Vermeulen joined San Francisco based Genentech in 2023 as head of the Discovery Oncology department. In 2017 he was appointed as professor of Molecular Oncology at the University of Amsterdam, as youngest professor of the institute ever. The combination of fundamental research and clinical work has provided him with a unique insight into the needs of patients as well as the opportunities that state-of-the-art science provides to address these. Amsterdam UMC based Vermeulen Lab seeks to elucidate the origin, the evolution and the heterogeneity of colorectal cancer.

Professor Peter Hoskin trained in clinical oncology at the Royal Marsden Hospital London and has been consultant in clinical oncology at Mount Vernon Cancer Centre, Northwood UK since 1992. He is Professor in Clinical Oncology in the University of Manchester and honorary consultant in clinical oncology at the Christie Hospital, Manchester and University College Hospital, London. Personal research interests focus on radiosensitisation, biomarkers, radiotherapy quality assurance, palliative radiotherapy, and brachytherapy. He is a member of the GEC ESTRO committee and past member of the ESTRO Board.

Professor Dave Fuller is professor and radiation oncologist in MD Anderson, Houston. His research focus remains development of evidence-based "personalized radiotherapy" techniques by incorporation of novel imaging methodologies. To date, the bulk of his work has focused on improving multimodality (e.g. PET-CT, MRI, US) imaging for target delineation in the multi-institutional setting. As a radiation oncologist with informatics certification and formal medical physics training, and is uniquely positioned to execute image-guided radiotherapy clinical trials. His long-term goal is to incorporate quantitative imaging biomarkers for risk stratification, adaptive therapy planning, and/or surrogate endpoint use in head and neck cancer.

Professor Matthias Guckenberger is Chairman of the Department of Radiation Oncology and full Professor at the University Hospital Zurich and University of Zurich. He is president of the European Society for Radiation Oncology (ESTRO) and is member of the EORTC Radiation Oncology Science Council. His clinical and research focus is image-guided high-precision radiotherapy, especially for lung cancer, prostate cancer and oligometastatic disease. The scientific achievements have been acknowledged with several national and international awards.

Ms. Liz Salmi is Communications & Patient Initiatives Director for OpenNotes at Beth Israel Deaconess Medical Center in Boston, MA. In this role, Liz aims to better understand the changing nature of patient-clinician communication in an age of increasing health information transparency. She does this by working alongside clinicians, hospitals, health systems, researchers, and most importantly, in partnership with patient advocates. In 2021, Liz and colleagues were awarded $12.8 million from the National Cancer Institute to determine optimal methods for patient enrollment in a cancer registry—designed in partnership with patients. Liz was named e-Patient of the Year by the Society for Participatory Medicine. She served on the board of directors for National Brain Tumor Society. Liz received the 2024 SNO Jan Esenwein Award for Public Service in Neuro-Oncology.

Mr. Jolanda van Boven geeft onderwijs, nascholing en adviezen op het gebied van het gezondheidsrecht gericht op zorgaanbieders in de eerste- en tweedelijns gezondheidzorg. Daarnaast beschikt ze over expertise op het gebied van privacywet en regelgeving in ketensamenwerking. Dit betreft zowel ketensamenwerking in de gezondheidszorg als in het publieke domein en het veiligheidsdomein. Ze is medeoprichter van de Leertuin Samenwerken aan Zorg & Veiligheid. Haar werk in deze context legt nadruk op het ontwikkelen van beleid, juridische richtlijnen en praktische handvatten voor een effectievere en juridisch verantwoorde samenwerking tussen zorginstellingen.

Professor dr. ir. Mathieu Weggeman is hoogleraar Organisatiekunde en Innovatie Management aan de TU Eindhoven, met een focus op innovatieprocessen in technologie-, kennisintensieve en culturele organisaties. Zijn onderzoek richt zich op thema's zoals leidinggeven aan professionals, strategieformulering, teamflow, en de invloed van esthetiek op kennisproductiviteit. Zijn boek "Leiding geven aan professionals? Niet doen!" won in 2008 de prijs voor Managementboek van het Jaar. Weggeman is een creatieve en licht anarchistische denker, meer gericht op mensen dan op structuren, en geïnspireerd door vakmanschap en bescheidenheid. Hij heeft een kritische blik op veramerikanisering en ziet de netwerkgeneratie als een kans voor innovatie en samenwerking.